In prostate cancer, FX11 treatment mitigates lactate-mediated angiogenesis and tumor cell migration [52], and similarly, FX11 inhibits LDHA-dependent cell proliferation, migration, and invasion in papillary thyroid carcinoma both in vitro and in vivo [175]. Here, LDHA is linked to neoplasm.